Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants

Autor: Luger, T, Boguniewicz, M, Carr, W, Cork, M, Deleuran, M, Eichenfield, L, Eigenmann, P, Folster-Holst, R, Gelmetti, C, Gollnick, H, Hamelmann, E, Hebert, AA, Muraro, A, Oranje, AP, Paller, AS, Paul, C, Puig, L, Ring, J, Siegfried, E, Spergel, JM, Stingl, G, Taieb, A, Torrelo, A, Werfel, T, Wahn, U
Rok vydání: 2015
Předmět:
Zdroj: PEDIATRIC ALLERGY AND IMMUNOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
ISSN: 0905-6157
Popis: Atopic dermatitis (AD) is a distressing dermatological disease, which is highly prevalent during infancy, can persist into later life and requires long-term management with anti-inflammatory compounds. The introduction of the topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, more than 10yr ago was a major breakthrough for the topical anti-inflammatory treatment of AD. Pimecrolimus 1% is approved for second-line use in children (2yr old) and adults with mild-to-moderate AD. The age restriction was emphasized in a boxed warning added by the FDA in January 2006, which also highlights the lack of long-term safety data and the theoretical risk of skin malignancy and lymphoma. Since then, pimecrolimus has been extensively investigated in short- and long-term studies including over 4000 infants (
Databáze: OpenAIRE
Externí odkaz: